Literature DB >> 25037113

Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity.

Chiara Cristina Bortolasci, Heber Odebrecht Vargas, André Souza-Nogueira, Estefania Gastaldello Moreira, Sandra Odebrecht Vargas Nunes, Michael Berk, Seetal Dodd, Décio Sabbatini Barbosa, Michael Maes.   

Abstract

Background The metabolic syndrome (MetS) is a complex of multiple risk factors that contribute to the onset of cardiovascular disorder, including lowered levels of high-density lipoprotein (HDL) and abdominal obesity. Smoking, mood disorders, and oxidative stress are associated with the MetS. Paraoxonase (PON)1 is an antioxidant bound to HDL, that is under genetic control by functional polymorphisms in the PON1 Q192R coding sequence. Aims and methods This study aimed to delineate the associations of the MetS with plasma PON1 activity, PON1 Q192R genotypes, smoking, and mood disorders (major depression and bipolar disorder), while adjusting for HDL cholesterol, body mass index, age, gender, and sociodemographic data. We measured plasma PON1 activity and serum HDL cholesterol and determined PON1 Q192R genotypes through functional analysis in 335 subjects, consisting of 97 with and 238 without MetS. The severity of nicotine dependence was measured using the Fagerström Nicotine Dependence Scale. Results PON1 Q192R functional genotypes and PON1 Q192R genotypes by smoking interactions were associated with the MetS. The QQ and QR genotypes were protective against MetS while smoking increased metabolic risk in QQ carriers only. There were no significant associations between PON1 Q192R genotypes and smoking by genotype interactions and obesity or overweight, while body mass index significantly increased MetS risk. Smoking and especially severe nicotine dependence are significantly associated with the MetS although these effects were no longer significant after considering the effects of the smoking by PON1 Q192R genotype interaction. The MetS was not associated with mood disorders, major depression or bipolar disorder. Discussion PON1 Q192R genotypes and genotypes by smoking interactions are risk factors for the MetS that together with lowered HDL and increased body mass and age contribute to the MetS.

Entities:  

Keywords:  Cardiovascular; Depression; HDL cholesterol; Metabolic syndrome; Oxidative stress; Paraoxonase 1

Mesh:

Substances:

Year:  2014        PMID: 25037113      PMCID: PMC6837660          DOI: 10.1179/1351000214Y.0000000093

Source DB:  PubMed          Journal:  Redox Rep        ISSN: 1351-0002            Impact factor:   4.412


  61 in total

Review 1.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

2.  Circulating levels of adiponectin, orexin-A, ghrelin and the antioxidant paraoxonase-1 in metabolic syndrome.

Authors:  O Tabak; R Gelişgen; H Cicekçi; E Senateş; F Erdenen; C Müderrisoğlu; H Aral; H Uzun
Journal:  Minerva Med       Date:  2012-08       Impact factor: 4.806

3.  Persistent elevation of paraoxonase-1 specific enzyme activity after weight reduction in obese non-diabetic men with metabolic syndrome.

Authors:  Kae-Woei Liang; Wen-Jane Lee; I-Te Lee; Wen-Lieng Lee; Shih-Yi Lin; Shih-Lan Hsu; Chu-Jen Wan; Chen-Yuan Yu; I-Chen Tsai; Chia-Po Fu; Chih-Tai Ting; Wayne H-H Sheu
Journal:  Clin Chim Acta       Date:  2011-06-17       Impact factor: 3.786

Review 4.  Exercising the worry away: how inflammation, oxidative and nitrogen stress mediates the beneficial effect of physical activity on anxiety disorder symptoms and behaviours.

Authors:  S Moylan; H A Eyre; M Maes; B T Baune; F N Jacka; M Berk
Journal:  Neurosci Biobehav Rev       Date:  2013-02-13       Impact factor: 8.989

Review 5.  Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies.

Authors:  Floriana S Luppino; Leonore M de Wit; Paul F Bouvy; Theo Stijnen; Pim Cuijpers; Brenda W J H Penninx; Frans G Zitman
Journal:  Arch Gen Psychiatry       Date:  2010-03

6.  A functional polymorphism of PON1 interferes with microRNA binding to increase the risk of ischemic stroke and carotid atherosclerosis.

Authors:  Mu-En Liu; Yi-Chu Liao; Ruey-Tay Lin; Yung-Song Wang; Edward Hsi; Hsiu-Fen Lin; Ku-Chung Chen; Suh-Hang H Juo
Journal:  Atherosclerosis       Date:  2013-02-21       Impact factor: 5.162

7.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

8.  Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk.

Authors:  Larry Baum; Ho Keung Ng; Kam Sang Woo; Brian Tomlinson; Timothy Hudson Rainer; Xiangyan Chen; Wing Sze Cheung; Daniel Kam Yin Chan; G Neil Thomas; Cindy See Wai Tong; Ka Sing Wong
Journal:  Clin Biochem       Date:  2006-02-09       Impact factor: 3.281

9.  Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases.

Authors:  Dmitry Litvinov; Halleh Mahini; Mahdi Garelnabi
Journal:  N Am J Med Sci       Date:  2012-11

10.  Is it smoking or related lifestyle variables that increase metabolic syndrome risk?

Authors:  Mikael Rabaeus; Patricia Salen; Michel de Lorgeril
Journal:  BMC Med       Date:  2013-09-03       Impact factor: 8.775

View more
  1 in total

1.  Generalized Anxiety Disorder (GAD) and Comorbid Major Depression with GAD Are Characterized by Enhanced Nitro-oxidative Stress, Increased Lipid Peroxidation, and Lowered Lipid-Associated Antioxidant Defenses.

Authors:  Michael Maes; Kamila Landucci Bonifacio; Nayara Rampazzo Morelli; Heber Odebrecht Vargas; Estefânia Gastaldello Moreira; Drozdstoy St Stoyanov; Décio Sabbatini Barbosa; André F Carvalho; Sandra Odebrecht Vargas Nunes
Journal:  Neurotox Res       Date:  2018-05-07       Impact factor: 3.911

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.